Skip to content
Board of Directors
Research and development
Immunotherapy of cancer
Board of Directors and Management
Articles of association
Share and owner information
Preferential Rights Issue Q4 2021
Preferential Rights Issue Q1 2021
Year End Reports
Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business update
Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
Interim report January–March 2022
Alligator Bioscience publishes Annual Report for 2021
Do your settings below. Or read our
These cookies are not optional. They are needed for the website to function.
In order for us to improve the website's functionality and structure, based on how the website is used.
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.